Cargando…

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

Hypertension and proteinuria are commonly observed side-effects for anti-angiogenic drugs targeting the VEGF pathway. In most cases, hypertension can be controlled by prescription of anti-hypertensive (AH) therapy, while proteinuria often requires dose reductions or dose delays. We aimed to construc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keizer, Ron J., Gupta, Anubha, Mac Gillavry, Melvin R., Jansen, Mendel, Wanders, Jantien, Beijnen, Jos H., Schellens, Jan H. M., Karlsson, Mats O., Huitema, Alwin D. R.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer US 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921067/ https://www.ncbi.nlm.nih.gov/pubmed/20652729 http://dx.doi.org/10.1007/s10928-010-9164-2

Ejemplares similares

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
por: Soto, Elena, et al.
Publicado: (2010)

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011)

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
por: Keizer, Ron J, et al.
Publicado: (2015)

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
por: Boss, D S, et al.
Publicado: (2012)

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents
por: Zandvliet, Anthe S., et al.
Publicado: (2009)

Evaluation of α(2)-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies
por: Keizer, Ron J., et al.
Publicado: (2011)

Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: Verheijen, Remy B., et al.
Publicado: (2017)

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
por: Crombag, Marie-Rose B.S., et al.
Publicado: (2016)

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy
por: van Hasselt, J. G. Coen, et al.
Publicado: (2014)

Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”
por: van Hasselt, J. G. Coen, et al.
Publicado: (2015)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
por: Hendrikx, Jeroen J M A, et al.
Publicado: (2020)

Fixed Dosing of Monoclonal Antibodies in Oncology
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
por: Jager, Nynke GL, et al.
Publicado: (2013)

Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants
por: Shumaker, Robert, et al.
Publicado: (2015)

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
por: Embaby, Alaa, et al.
Publicado: (2022)

Protein versus DNA as a marker for peripheral blood mononuclear cell counting
por: Jansen, Robert S., et al.
Publicado: (2009)

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
por: van Eijk, Maarten, et al.
Publicado: (2019)

Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
por: Verrest, Luka, et al.
Publicado: (2021)

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS
por: de Jong, Karen A.M., et al.
Publicado: (2021)

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
por: Verrest, Luka, et al.
Publicado: (2021)

The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer
por: Lin, Lishi, et al.
Publicado: (2022)

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis
por: Jacobs, Bart A.W., et al.
Publicado: (2019)

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2019)

DS-7080a, a Selective Anti-ROBO4 Antibody, Shows Anti-Angiogenic Efficacy with Distinctly Different Profiles from Anti-VEGF Agents
por: Isumi, Yoshitaka, et al.
Publicado: (2020)

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach
por: Damoiseaux, David, et al.
Publicado: (2023)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

LINC02688 and PP7080 as novel biomarkers in early diagnosis of gastric cancer
por: Fattahi, Sadegh, et al.
Publicado: (2021)

A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens
por: van der Heijden, Lisa, et al.
Publicado: (2022)

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Phase I pharmacological study of continuous chronomodulated capecitabine treatment
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors
por: Nijenhuis, Cynthia M., et al.
Publicado: (2016)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
por: Damoiseaux, David, et al.
Publicado: (2022)

The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials
por: van Eijk, Maarten, et al.
Publicado: (2022)

Mutations in pmrB Confer Cross-Resistance between the LptD Inhibitor POL7080 and Colistin in Pseudomonas aeruginosa
por: Romano, Keith P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kgncreha95ksmudkge3hkjb0r3